Európai Unió - norvég - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatide - diabetes mellitus, type 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Európai Unió - norvég - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Európai Unió - norvég - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, type 2 - legemidler som brukes i diabetes - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 og 5.

Európai Unió - norvég - EMA (European Medicines Agency)

zoetis belgium sa - meloksikam - oxicams - hunder - lindring av betennelse og smerte i både akutte og kroniske muskuloskeletale sykdommer hos hunder.

Európai Unió - norvég - EMA (European Medicines Agency)

vétoquinol sa - emodepside, praziquantel, tigolaner - anthelmintics, - katter - for cats with, or at risk from, mixed parasitic infestations. the veterinary medicinal product is exclusively indicated when ectoparasites, cestodes and nematodes are targeted at the same time.

Európai Unió - norvég - EMA (European Medicines Agency)

zoetis belgium sa - dibotermin alfa - benmorfogenetiske proteiner - hunder - osteoinductive agent for bruk i behandling av lang-benbrudd som et tillegg til standard kirurgisk behandling ved hjelp av åpne brudd reduksjon i hunder.

Európai Unió - norvég - EMA (European Medicines Agency)

emdoka bvba - meloksikam - oxicams - horses; pigs; cattle - cattlefor bruk i akutt luftveisinfeksjon med passende antibiotikabehandling for å redusere kliniske tegn. for bruk i diaré i kombinasjon med oral rehydreringsterapi for å redusere kliniske tegn i kalver på over en uke og unge, ikke-lakterende storfe. for tilleggsbehandling i behandling av akutt mastitt, i kombinasjon med antibiotikabehandling. pigsfor bruk i noninfectious locomotor lidelser til å redusere symptomer på halthet og betennelser. for tilleggsbehandling i behandling av puerperal septikemi og toksemi (mastitits-metritis-agalactia syndrom) med passende antibiotikabehandling. horsesfor bruk i lindre betennelser og lindring av smerter i både akutte og kroniske muskel-og skjelettlidelser. for lindring av smerte assosiert med hestekolikk. hunder: lindring av inflammasjon og smerter i både akutte og kroniske muskel-og skjelettlidelser. reduksjon av postoperativ smerte og betennelse etter ortopedisk og bløtvev kirurgi. cats:reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Norvégia - norvég - Statens legemiddelverk

accord healthcare b.v. - cinacalcethydroklorid - tablett, filmdrasjert - 30 mg

Norvégia - norvég - Statens legemiddelverk

accord healthcare b.v. - cinacalcethydroklorid - tablett, filmdrasjert - 60 mg

Norvégia - norvég - Statens legemiddelverk

accord healthcare b.v. - cinacalcethydroklorid - tablett, filmdrasjert - 90 mg